A new phase of CFTR treatment for cystic fibrosis?

被引：1

作者：

Bell, Scott C. ^{[1
,2
]}

机构：

[1] QIMR Berghofer Med Res Inst, Brisbane, Qld 4006, Australia

[2] Prince Charles Hosp, Brisbane, Qld 4032, Australia

来源：

LANCET RESPIRATORY MEDICINE | 2015年 / 3卷 / 09期

关键词：

CLINICAL-TRIALS NETWORK; G551D MUTATION; IVACAFTOR; GENE; EFFICACY; SAFETY;

D O I：

10.1016/S2213-2600(15)00282-9

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

引用

页码：662 / 663

页数：2

共 15 条

[1]

Alton EricW.F.W., 2015, The Lancet Respiratory Medicine

[2] Structural changes of CFTR R region upon phosphorylation: a plastic platform for intramolecular and intermolecular interactions [J].

Bozoky, Zoltan ;

Krzeminski, Mickael ;

Chong, P. Andrew ;

Forman-Kay, Julie D. .

FEBS JOURNAL, 2013, 280 (18) :4407-4416

[3]

Brimelow A., FUNDING SHORTFALL PU

[4] Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation [J].

Davies, Jane C. ;

Wainwright, Claire E. ;

Canny, Gerard J. ;

Chilvers, Mark A. ;

Howenstine, Michelle S. ;

Munck, Anne ;

Mainz, Jochen G. ;

Rodriguez, Sally ;

Li, Haihong ;

Yen, Karl ;

Ordonez, Claudia L. ;

Ahrens, Richard .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187 (11) :1219-1225

[5] Guideline on the design and conduct of cystic fibrosis clinical trials: The European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN) [J].

De Boeck, K. ;

Bulteel, V. ;

Tiddens, H. ;

Wagner, T. ;

Fajac, I. ;

Conway, S. ;

Dufour, F. ;

Smyth, A. R. ;

Lee, T. ;

Sermet, I. ;

Kassai, B. ;

Elborn, S. .

JOURNAL OF CYSTIC FIBROSIS, 2011, 10 :S67-S74

[6] Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation [J].

De Boeck, Kris ;

Munck, Anne ;

Walker, Seth ;

Faro, Albert ;

Hiatt, Peter ;

Gilmartin, Geoffrey ;

Higgins, Mark .

JOURNAL OF CYSTIC FIBROSIS, 2014, 13 (06) :674-680

[7] Airway gene transfer in a non-human primate: Lentiviral gene expression in marmoset lungs [J].

Farrow, N. ;

Miller, D. ;

Cmielewski, P. ;

Donnelley, M. ;

Bright, R. ;

Parsons, D. W. .

SCIENTIFIC REPORTS, 2013, 3

[8] The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases [J].

Goss, CH ;

Mayer-Hamblett, N ;

Kronmal, RA ;

Ramsey, B .

ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (11) :1505-1528

[9] Cystic Fibrosis Gene Therapy in the UK and Elsewhere [J].

Griesenbach, Uta ;

Pytel, Kamila M. ;

Alton, Eric W. F. W. .

HUMAN GENE THERAPY, 2015, 26 (05) :266-275

[10] Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial [J].

Kerem, Elton ;

Konstan, Michael W. ;

De Boeck, Kris ;

Accurso, Frank J. ;

Sermet-Gaudelus, Isabelle ;

Wilschanski, Michael ;

Elborn, J. Stuart ;

Melotti, Paola ;

Bronsveld, Inez ;

Fajac, Isabelle ;

Malfroot, Anne ;

Rosenbluth, Daniel B. ;

Walker, Patricia A. ;

McColley, Susanna A. ;

Knoop, Christiane ;

Quattrucci, Serena ;

Rietschel, Ernst ;

Zeitlin, Pamela L. ;

Barth, Jay ;

Elfring, Guy L. ;

Welch, Ellen M. ;

Branstrom, Arthur ;

Spiegel, Robert J. ;

Peltz, Stuart W. ;

Ajayi, Temitayo ;

Rowe, Steven M. .

LANCET RESPIRATORY MEDICINE, 2014, 2 (07) :539-547

← 1 2 →